Atossa Genetics (NASDAQ:ATOS), Inc. is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.
The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence. In addition, Atossa has developed a proprietary intraductal microcatheter platform that enables direct delivery of therapeutic agents into the milk ducts, aiming to concentrate treatment at the tumor site while minimizing systemic side effects. Complementing these programs are diagnostic initiatives that utilize nipple aspirate fluid analysis to identify molecular changes associated with early-stage disease.
Founded in 2009, Atossa Genetics has advanced its clinical programs through collaborations with leading academic and research institutions across North America. The company’s trials are conducted at major cancer centers and specialized breast health clinics, reflecting its commitment to rigorous scientific evaluation and patient-centric development.
Under the leadership of CEO Steven C. Quay, MD, PhD, Atossa’s management team brings extensive experience in oncology drug development, regulatory affairs, and commercial strategy. The company continues to prioritize innovation in breast health by advancing its proprietary therapeutic and diagnostic platforms toward regulatory milestones and potential commercialization.
